South San Francisco, CA
Second Genome Launches Study of the Relationship Between Microbiome and Central Nervous System in Autism Spectrum Disorders
October 3, 2017, South San Francisco, CA
Second Genome Announces Appointments in Human Resources, Finance to Support Corporate Growth
December 7, 2016, South San Francisco, CA
Second Genome Partners with King’s College London to Evaluate the Influence of the Microbiome in Landmark EAT Study
October 11, 2016, South San Francisco, CA
Monsanto Collaborates with Second Genome to use Microbiome Technology Platform to Accelerate Protein Discovery
September 6, 2016, South San Francisco, CA & St. Louis, MO
Second Genome Appoints Glenn Nedwin, Ph.D., as Chief Executive Officer
July 13, 2016, South San Francisco, CA
Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund
April 20, 2016, South San Francisco, CA
Second Genome Announces Inflammatory Bowel Disease Research Alliance with the APC Microbiome Institute at University College Cork
April 27, 2015, South San Francisco, CA
Second Genome Advances Lead Microbiome Drug Development Program in Phase I Clinical Trial as a Treatment for Inflammatory Bowel Disease
January 12, 2015, South San Francisco, CA